CD163 and breast carcinoma: Although they are less well-studied, CD20+ B cells, which play an integral role in humoral immunity and shape the functions of other immune cells, and CD163+ cells, a marker of anti-inflammatory M2 macrophages [30], may also have prognostic value in breast cancer [31–34].